Calamos Wealth Management LLC Raises Stock Position in Amgen Inc. (NASDAQ:AMGN)

Calamos Wealth Management LLC lifted its stake in Amgen Inc. (NASDAQ:AMGN) by 2.2% in the 4th quarter, HoldingsChannel reports. The firm owned 2,459 shares of the medical research company’s stock after buying an additional 54 shares during the quarter. Calamos Wealth Management LLC’s holdings in Amgen were worth $641,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors also recently modified their holdings of AMGN. Capital Performance Advisors LLP bought a new stake in shares of Amgen during the 3rd quarter valued at $25,000. Legacy Investment Solutions LLC purchased a new position in Amgen during the 3rd quarter valued at about $29,000. Matrix Trust Co bought a new stake in Amgen during the third quarter worth about $36,000. Heck Capital Advisors LLC purchased a new stake in Amgen in the fourth quarter worth about $36,000. Finally, Livelsberger Financial Advisory bought a new position in shares of Amgen during the third quarter valued at approximately $56,000. Hedge funds and other institutional investors own 76.50% of the company’s stock.

Amgen Trading Up 0.1 %

Amgen stock opened at $289.02 on Wednesday. The company has a current ratio of 1.32, a quick ratio of 0.96 and a debt-to-equity ratio of 7.55. Amgen Inc. has a 12-month low of $253.30 and a 12-month high of $346.85. The firm has a market capitalization of $155.36 billion, a price-to-earnings ratio of 37.01, a P/E/G ratio of 2.87 and a beta of 0.56. The firm has a 50 day moving average of $270.95 and a 200 day moving average of $303.82.

Amgen (NASDAQ:AMGN) last announced its quarterly earnings data on Tuesday, February 4th. The medical research company reported $5.31 EPS for the quarter, beating the consensus estimate of $5.04 by $0.27. Amgen had a net margin of 13.00% and a return on equity of 168.35%. As a group, research analysts predict that Amgen Inc. will post 19.56 earnings per share for the current year.

Amgen Increases Dividend

The firm also recently announced a quarterly dividend, which will be paid on Friday, March 7th. Investors of record on Friday, February 14th will be given a dividend of $2.38 per share. The ex-dividend date is Friday, February 14th. This represents a $9.52 annualized dividend and a dividend yield of 3.29%. This is a boost from Amgen’s previous quarterly dividend of $2.25. Amgen’s dividend payout ratio (DPR) is currently 115.24%.

Wall Street Analysts Forecast Growth

Several analysts recently weighed in on the company. TD Cowen upped their price target on Amgen from $381.00 to $383.00 and gave the stock a “buy” rating in a research note on Monday, October 21st. Royal Bank of Canada reissued an “outperform” rating and issued a $324.00 target price on shares of Amgen in a report on Friday, January 24th. Piper Sandler Companies reaffirmed an “overweight” rating and set a $310.00 price target on shares of Amgen in a report on Thursday, January 2nd. Leerink Partners reduced their price objective on Amgen from $349.00 to $302.00 in a report on Wednesday, November 27th. Finally, Sanford C. Bernstein initiated coverage on shares of Amgen in a research note on Thursday, October 17th. They set an “outperform” rating and a $380.00 target price on the stock. Two investment analysts have rated the stock with a sell rating, twelve have issued a hold rating, thirteen have issued a buy rating and one has issued a strong buy rating to the company. According to MarketBeat.com, the company currently has a consensus rating of “Hold” and an average target price of $314.00.

Amgen Profile

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.